Glucosamine and Chondroitin in Preventing Inflammation in Overweight Patients

GLANCE 2 - Glucosamine and Chondroitin (G&C) Effects Study

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03827161

Enrollment

Registered

2019-02-01

Start date

2017-08-01

Completion date

2018-12-01

Last updated

2019-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subject, Overweight

Brief summary

This trial studies glucosamine and chondroitin in preventing inflammation in overweight patients. Chronic inflammation contributes to cancer formation, and biomarkers of inflammation have been associated with cancer risk. Glucosamine and chondroitin may prevent inflammation and this trial may help identify the bacteria that help process them in the gut.

Interventions

DIETARY_SUPPLEMENTGlucosamine

Given PO

OTHERPlacebo

Given PO

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

-Individuals from the Greater Seattle area who are overweight (body mass index \[BMI\] of 25-32.5 kg/m\^2)

Exclusion criteria

* Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or inflammatory conditions (including autoimmune and inflammatory diseases) * Pregnancy or lactation * Currently on a weight-loss diet * BMI (body mass index) \< 25 or \> 32.5 kg/m\^2 * Alcohol intake of greater than 2 drinks/day (2 drinks being equivalent to 720 ml beer, 240 ml wine or 90 ml spirits) * Current use of prescription or over-the-counter medications other than oral contraceptives and hormone secreting intrauterine device (IUD)s, multivitamin pills or infrequent use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), or use of aspirin or NSAIDs more than 2 days per week * Abnormal renal, liver or metabolic test * Inability to swallow pills * Known allergy to shellfish * Not willing to take pills made from shellfish or animal sources * Intention to relocate out of study area within next 2 months * Any antibiotic use in the past 6 months

Design outcomes

Primary

Measure	Time frame	Description
Effects of glucosamine sulfate/chondroitin sulfate tablet (G&C) on gut microbial community modulation	Up to 2 years	shifts in the bacterial communities within person based on clustering of operational taxonomic units (OTU) at 97% utilizing principal coordinate analysis \[PCOA\]).
Effects of G&C on serum C-reactive protein (CRP)	Up to 2 years	evaluated using a generalized estimating equation which accounts for variation due to repeated measures within an individual

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026